{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-025180","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.458699+00:00","generated_at":"2026-05-31T12:03:25.088101+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OPKO reports Q2 net loss $10.3M; enters $250M note deal, plans $100M buyback","bullets":["Q2 total revenues $182.2M (down from $265.4M YoY); operating loss $61.7M vs income $7.0M; net loss $0.01/share.","NGENLA global launch ongoing; earned $6.3M gross profit share from Pfizer in Q2 (up from $3.8M).","Entered $250M note purchase agreement with HealthCare Royalty secured by NGENLA profit share; retains milestone upside.","Board authorized $100M share repurchase program (~10.1% of shares outstanding).","Sale of BioReference laboratory assets to Labcorp for $237.5M expected close end of Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-025180","json":"https://secwatch.observer/filing/0001437749-24-025180.json","markdown":"https://secwatch.observer/filing/0001437749-24-025180.md","text":"https://secwatch.observer/filing/0001437749-24-025180.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000143774924025180/0001437749-24-025180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000143774924025180/opk20240801_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:03:25.088101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}